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Purpose	Metabolic syndrome is a set of metabolic risk factors associated with increased risk of developing
cardiovascular disease and type 2 diabetes mellitus. We retrospectively evaluated the effectiveness
of a lifestyle modification program (Heart WATCH) geared toward reducing development of chronic
disease in women deemed at risk for metabolic syndrome, prediabetes and/or cardiovascular disease.
Methods	
Our institution’s Heart WATCH program consists of screening sessions with a multidisciplinary team
(physician/nurse, nutritionist and psychologist), a minimum of three visits with a nurse practitioner and
weekly follow-up phone calls for a 14-week period. Sociodemographic variables were obtained at initial
visit. Biometric testing indices and self-reported clinical and behavioral health measures were recorded
pre- and postintervention, and compared using paired t-tests or McNemar’s test as appropriate.
Results		Heart WATCH enrolled 242 women from November 2006 to April 2014, and 193 (80%) completed all
phases of the 14-week lifestyle intervention. Postintervention, participants demonstrated improved health
status in all areas and improved significantly in the following areas: diet/nutrition (P=0.014), exercise
(P<0.001), stress (P<0.0001), quality of life (P=0.003), weight (P<0.0001), waist circumference (P=0.01)
and total cholesterol (P=0.019). Clinically meaningful improvements were realized by participants who
moved to a healthier classification in a number of vital signs and blood panel indices.
Conclusions	
These findings suggest the “elevated risk profile” for women with components of metabolic syndrome
can be reversed through a lifestyle program focused on reducing risk factors associated with
cardiovascular disease and prediabetes. Future research is needed to determine mechanisms of
risk reduction as well as optimal patient-centered and culturally appropriate approaches to weight
management. (J Patient-Centered Res Rev. 2015;2:56-63.)
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Metabolic syndrome (MetS) is a constellation of
metabolic risk factors that are associated with increased
risk of developing cardiovascular disease and type
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2 diabetes mellitus.1-3 It is estimated that individuals
with MetS are 2–2.5 times more likely to develop
cardiovascular disease compared to those without the
syndrome.3 The predominant risk factors that make up
MetS are abdominal obesity (i.e. waist circumference
of ≥ 35 inches in women and ≥ 40 inches in men or
body mass index [BMI] ≥ 30 kg/m2)4-6 and insulin
resistance.5,7 Both of these adverse outcomes frequently
result from physical inactivity6 and a high-fat, highOriginal Research

cholesterol diet.8 Other risk factors for MetS include
raised triglycerides (> 150 mg/dL [or 1.7 mmol/L])
or specific treatment for this lipid abnormality,
reduced high-density lipoprotein (HDL) cholesterol
(< 40 mg/dL [or 1.03 mmol/L] in men and < 50 mg/dL
[or 1.29 mmol/L] in women) or specific treatment for
this lipid abnormality, raised blood pressure (systolic
> 130 mmHg or diastolic > 85 mmHg) or treatment
of previously diagnosed hypertension, raised fasting
plasma glucose (> 100 mg/dL [or 5.6 mmol/L]) or
previously diagnosed type 2 diabetes.1,5,9
Several diagnostic criteria for MetS have been
proposed, including benchmarks from the World Health
Organization (WHO), the European Group for Study
of Insulin Resistance (EGIR), the National Cholesterol
Education Program Adult Treatment Panel III (ATP III),
the American Association of Clinical Endocrinologists
(AACE) and the International Diabetes Foundation
(IDF).1-3,10 Differences in these diagnoses reflect
an addition or exclusion of a specific criterion. For
example, insulin resistance is a clinical measure for
diagnosing MetS in WHO, EGIR and AACE criteria,
but not in the criteria proposed by ATP III or IDF.1 As
a result of the varying criteria, the reported prevalence
of MetS varies greatly. Findings from a meta-analysis
conducted by Galassi and colleagues examining the
association between MetS and cardiovascular disease
in prospective studies reported the prevalence of MetS
ranged from 38% to 77% when using ATP III and
WHO classifications, respectively.10
According to findings from the National Health
and Nutrition Examination Survey 2003–2006,
which used the ATP III diagnostic criteria, the
age-adjusted prevalence of MetS in adults was 34%.5
Differences in MetS prevalence were observed by
age, sex and BMI.5 Specifically, each progressive
20-year age group resulted in an increased prevalence of
MetS in both men and women. For example, women
age ≥ 60 years were more than six times as likely to
meet the criteria for MetS compared with women
20–39 years of age.5 In addition, prevalence increased
as mean BMI increased. Compared to normal weight
and underweight women, overweight and obese
women were approximately 5.5 and 17 times more
likely to have MetS, respectively.5
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Specific guidelines for treating MetS remain unclear.
The Heart WATCH (Women Acting To Create Heart
Health) program at our primary institution is based on
diabetes prevention recommendations and receives
reimbursement from patient health insurance for the
diagnosis of metabolic syndrome and cardiovascular risk
factors. Patients were referred to the program by their
physicians and were accepted into the program if they had
at least one MetS risk factor. Our Heart WATCH program
defines MetS using the IDF criteria. This definition
includes abdominal obesity plus two of the following:
elevated triglycerides, reduced HDL cholesterol, elevated
blood pressure or elevated fasting plasma glucose.
The purpose of this study was to evaluate the impact of
Heart WATCH as a lifestyle modification program geared
toward reducing the risk of chronic disease developing in
women who have MetS, prediabetes and cardiovascular
disease risk factors. Regarding the outcomes identified
in this manuscript, two primary questions were asked. 1)
Was there significant weight loss related to participation
in Heart WATCH? 2) Are there statistically significant
and clinically meaningful improvements in MetS risk
factors and health status indictors related to participation
in the Heart WATCH program?

METHODS

Study Design
We performed a retrospective evaluation of program
effectiveness using evidence-based quality improvement
measures and data collected as part of the Heart WATCH
program. Women were asked to provide information
before and after program intervention as part of a
quality improvement assessment of the program. The
investigative team received approval for accessing
available patient data from the local institutional review
board in December 2013 (Protocol #13-137MR). Heart
WATCH enrolled eligible women who presented to
our health system’s hospitals and clinics beginning in
November 2006 and through April 2014.
Heart WATCH Program Overview
The Heart WATCH program is implemented over a
14-week period. The first two visits, which occur over
the first two weeks, make up the screening process.
Intervention begins following confirmation of the
enrolled woman screening positive for at least one
MetS, prediabetes or cardiovascular risk factor. The
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intervention portion of Heart WATCH consists of a
12-week lifestyle modification program, and includes a
minimum of three visits along with weekly phone calls.
The visit schedule is described in detail in Table 1.
Measures
A number of measures were assessed in this program,
including sociodemographics, biometric testing
indices and self-reported clinical and behavioral
health measures. Sociodemographic variables were
collected at the initial screening visit and included
age, gender (all female) and zip code. Patients
were asked to complete self-reporting clinical and
behavioral health scales at the initial screening
visit and then again at the final intervention visit.
These measures included patient-reported processes
designed for Heart WATCH: an 8-item diet survey
(potential range 0–24), a 5-item exercise survey
(potential range 1–18) and a 3-item quality-of-life
survey (potential range 0–30). The diet, exercise
and quality-of-life surveys were compiled by the
program’s medical professionals. In addition, two
standardized measures were administered, the 10-

item (potential range 0–40) Perceived Stress Scale
(PSS-10)11 and the 9-item Patient Health Questionnaire
(PHQ-9).12 All biometrics, including height, weight,
BMI, blood pressure, heart rate, hip circumference,
waist circumference and body fat percentage, were
completed at the initial screening visit and again at the
final intervention visit. Measures were available for
women differentially depending on when measures
were fully incorporated into the preintervention
baseline and the follow-up assessment protocol.
Data Availability and Analyses
Because this was a retrospective evaluation of a clinicbased program, data was not collected systematically
and therefore was inconsistently available. Paired
t-tests were used to determine if patient scores from
pre- to postintervention were statistically different.
We assumed equal variances for these intraparticipant
analyses because participants served as their own
control and changes were expected for some but not
all participants. For the purpose of study analyses,
U.S. standard measurement units were used for all
blood panel biomarker data. Statistical analyses were

Table 1. Heart WATCH program description
Visit number
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Visit description

Screening Visit #1

Screening visit for cardiovascular disease risk factors. Visit includes biometric screening for
height, weight, blood pressure and heart rate; measurement of hip and waist circumference,
body mass index and body fat percentage; a physical examination; laboratory evaluations; and
a stress survey (PSS-10). Review of health history includes allergies, medications, surgeries,
hospitalizations and health condition.

Screening Visit #2

Visit includes discussion of the initial visit (Screening Visit #1) findings, with a focus on each
patient’s individual cardiovascular disease risk factors and proposed treatment plan.

Week #1

This 3-hour visit consists of a 45-minute visit with a dietician, a 45-minute visit with an exercise
therapist, 30 minutes with a nurse practitioner (NP), and 45 minutes with a behavioral health
specialist. Individualized plans for diet, exercise and stress control are developed and reviewed
with each patient. Patients receive resources to assist in meeting goals for diet and exercise,
including a food and exercise diary to monitor daily activities.

Weeks #2 – #5

Weekly phone calls from registered nurse (RN) coordinator are conducted to assist with any
concerns or questions, and to monitor diet, exercise and weight. Blood glucose and blood
pressure are measured if applicable.

Week #6

A 1-hour visit with the NP. Hip and waist circumference, body mass index and body fat
percentage are measured, and the patient’s food and exercise diary is reviewed.

Weeks #7 – #11

Weekly phone calls from RN coordinator to assist with any concerns, and to monitor diet,
exercise and weight. Blood glucose and blood pressure are measured if applicable.

Week #12

An in-person visit with the NP. Laboratory assessments are repeated. Physical evaluation
includes height, weight, blood pressure, heart rate, hip, waist, body mass index and body fat.
A detailed discussion of overall results, including lab tests, medications and changes in lifestyle,
is conducted.
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performed using SAS version 9.2 (SAS Institute Inc.,
Cary, NC). In addition, for each of the eight biometric
measures in which universal cut-offs were available,
we determined the number and percentage of patients
achieving one of three clinical status outcomes
postintervention: 1) Good = maintained normal status
or improved; 2) Borderline = suboptimal status with no
change; or 3) Poor = remained impaired or worsened.
Finally, we determined the total number of the five
MetS-defining factors present for each patient both
before and after Heart WATCH treatment. In this final
subanalysis, we expected a small sample size due
to the low number of patients who would have data
available on all five indicators; however, removing
cases without data for all five indicators was essential
to avoid erroneously counting patients as not having
MetS due to lack of viable data rather than truly scoring
below criterion thresholds.

RESULTS

A total of 242 women signed up for the program over
the study period. Of those initially enrolled patients,
193 (80%) completed all phases of the program and
made up the study population. Ages in this group ranged
from 27 to 90 years (mean age was 54 years). Racial
make-up was 75% Caucasian, 16% African American
and 9% unknown. About 21% of the women resided
within one of Milwaukee’s 10 inner city zip codes,
which annually experience the greatest degree of social
and health inequities.13
Table 2 displays the change in self-reported clinical
and behavioral health status indicators for program

participants pre- and postintervention. On average,
participants showed improvement in all clinical
and behavioral health status measures after completion
of the program. As shown, participants improved
significantly from pre- to postintervention on their
reports of diet/nutrition, exercise, stress, general health
and quality of life.
Table 3 displays the change in vital sign and blood
panel health status indicators for participants preand postintervention. On average, participants
improved significantly from pre- to postintervention
in weight and waist circumference. There was a small
postintervention increase in mean BMI, but this increase
was not statistically significant. Participants showed
improvement in all blood panel health status measures
after completion of the program. Improvements in mean
total cholesterol, mean triglycerides and mean glucose
were statistically significant. Slight improvements
in systolic blood pressure, diastolic blood pressure,
HDL cholesterol and low-density lipoprotein (LDL)
cholesterol were not statistically significant.
Table 4 provides a breakdown of the number and
percentage of patients achieving a “Good,” “Borderline”
or “Poor” clinical status outcome postintervention. Only
8% of patients achieved a normal BMI after completing
the program. However, far more patients achieved
a Good outcome on the other biometric measures:
61% had optimal LDL cholesterol, 59% had desirable
total cholesterol, 59% had normal glucose level, 56%
had normal diastolic blood pressure, 51% had normal
triglycerides, 32% had normal systolic blood pressure,

Table 2. Self-reported clinical and behavioral health status of Heart WATCH participants pre- and postintervention
Preintervention

Postintervention

Outcome variable

Mean

SD

Mean

SD

t

P

Diet/nutrition, n=45

11.27

2.73

18.49

3.20

-2.57

0.014

Exercise, n=48

4.50

3.26

8.19

4.09

-5.90

<0.0001

Stress (via PSS-10 questionnaire), n=142

16.05

7.51

13.11

6.99

5.80

<0.0001

Health (via PHQ-9 questionnaire), n=141

7.34

5.58

4.41

4.18

7.13

<0.0001

Quality of life, n=44

18.22

4.80

20.05

5.02

-3.20

0.003

SD, standard deviation.
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Table 3. Mean change in physical health status of Heart WATCH participants pre- and postintervention
Preintervention

Postintervention

Outcome variable

Mean

SD

Mean

SD

t

P

Body mass index, n=62

38.51

10.80

37.86

9.18

1.20

0.236

Weight, n=64

229.94

47.22

224.54

46.68

6.38

<0.0001

Waist circumference, n=64

43.90

5.86

43.23

6.04

2.53

0.014

Systolic blood pressure, n=84

126.74

18.18

126.54

16.75

0.12

0.90

Diastolic blood pressure, n=84

75.52

10.85

76.07

9.60

-0.53

0.59

Total cholesterol, n=46

204.39

36.58

187.63

33.14

2.44

0.019

LDL cholesterol, n=46

125.32

34.88

113.10

32.92

1.99

0.052

HDL cholesterol, n=41

45.58

10.18

46.02

12.94

-0.29

0.077

Triglycerides, n=45

181.93

80.47

154.87

64.05

2.84

0.007

Glucose, n=63

111.22

43.37

106.14

36.68

2.02

0.048

HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation.

Table 4. Postintervention clinical outcome status of biometric indicators of Heart WATCH participants
Clinical outcome status
1 = Good
(maintained normal
status or improved)

2 = Borderline
(suboptimal status
and no change)

3 = Poor
(remained impaired
or worsened)

5 (8%)

7 (11%)

50 (81%)

Systolic blood pressure, n=84

27 (32%)

40 (48%)

17 (20%)

Diastolic blood pressure, n=84

47 (56%)

29 (34%)

8 (10%)

Total cholesterol, n=46

27 (59%)

18 (39%)

1 (2%)

LDL cholesterol, n=46

28 (61%)

15 (33%)

3 (6%)

HDL cholesterol, n=41

7 (17%)

22 (54%)

12 (29%)

Triglycerides, n=45

23 (51%)

11 (24%)

11 (25%)

Glucose, n=63

37 (59%)

16 (25%)

10 (16%)

Biometric indicator
Body mass index, n=62

HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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and 17% had protective levels of HDL cholesterol.
Although fully 81% were obese or morbidly obese after
intervention, a far less proportion registered a Poor
outcome on the other biometric measures: 2% had high
total cholesterol, 6% had high LDL, 10% had high or
very high diastolic blood pressure, 16% had glucose
levels signifying diabetes, 20% had high or very high
systolic blood pressure, 25% had high or very high
triglycerides, and 29% had low (i.e. risky) HDL.

data points needed to determine presence or absence of
MetS both before and after the intervention on 27. Of
these 27, 8 did not have MetS pre-Heart WATCH and
19 did. Post-Heart WATCH, 11 of these 27 patients did
not have MetS while 16 did. Although this change was
not significant statistically (S=1.8, P=0.375), we felt it
important to note that three fewer patients had MetS
postintervention.

Of the 193 patients who completed the Heart WATCH
program, we were able to retrospectively obtain all

To address MetS by risk factor mitigation, emphasis is
often placed on lifestyle and behavioral changes such as
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increasing the amount and intensity of physical activity,
modifying diet and attempting to reduce weight.1 It
has been documented that higher aerobic capacity and
self-reported physical activity are inversely associated
with metabolic disorders and related conditions like
cardiovascular disease mortality, impaired glucose
tolerance and type 2 diabetes.14-19 Similarly, engaging
in physical activity predicts MetS incidence in a
dose-response manner. For instance, engaging in low
levels of physical activity was shown to increase the
incidence of MetS, whereas higher levels of physical
activity were associated with lower MetS incidence.18,19
A study by Ford et al. showed nearly twofold odds of
developing MetS among adults who did not engage in
moderate or vigorous physical activity compared to
their physically active counterparts (defined as at least
150 minutes of activity per week).20 Similar behavioral
programs geared toward weight reduction by focusing
on diet have been explored,21 given the salience and
potential for modifying dietary practices.
The benefits of weight reduction are numerous
and include improving all components of MetS.
Specifically, weight loss has been found to treat
adiposity, dyslipidemia, hypertension, insulin resistance
and hyperglycemia.22 Even small reductions in weight
have been shown to improve MetS risk factors, and it
is speculated that a 5–10% loss of initial body weight
can reduce triglycerides, increase HDL cholesterol, and
decrease fasting blood glucose, insulin and hemoglobin
A1c levels.23,24 One successful example is the Finnish
Diabetes Prevention Study, which showed that,
compared to the control group, the prevalence of MetS
was reduced among participants who had modest weight
reductions resulting from a lifestyle intervention.21
Another successful example of a behavioral intervention
is the HERITAGE Family Study, which examined the
impact of regular exercise to treat MetS, cardiovascular
disease and type 2 diabetes in men and women.2 In the
program, participants engaged in a 20-week aerobic
exercise regimen involving three sessions per week for a
duration of 30–50 minutes at varying intensities. Results
from this study showed that MetS risk factors decreased
as a result of the exercise training program. In addition,
30% of the participants who met the criteria for MetS
diagnosis at baseline no longer met the criteria upon
completion of the intervention.2

Original Research

Recommendations for change from existing studies
focus either on the provider or the patient. For health
care providers, additional education and training is
recommended since health care providers care for
patients with MetS.9 For patients, comprehensive
programs geared toward addressing physical activity2
and proper diet/nutrition have been recommended.9
Investigations in which primary care providers provide
counseling about diet and exercise have led to weight
loss of 2.5 kg or less in studies with timeframes ranging
from 6 to 18 months.2,9 Inadequate treatment contact may
be responsible for such a small amount of weight loss.
Given the requirements on providers’ time, an increase
in the frequency of provider-based obesity counseling
does not appear to be a practical solution.
Specific guidelines for treating MetS are unclear.
Additional gaps in the literature exist regarding best
practices for lifestyle and behavioral modification
interventions to address MetS within specific
populations, including older adults and retirees and
within targeted locations like workplaces.25 Despite
the increasing evidence of the benefits of lifestyle and
behavioral interventions for increasing physical activity
and improving diet, long-term adherence to either
modification remains poor. However, based on existing
literature, it is our opinion that behavioral and lifestyle
approaches for reducing MetS and cardiovascular risk
factors are the best evidence-based strategies to date
given the improvements, albeit modest, these strategies
provide in all components of MetS.
Based on recommendations from the literature on
areas for future research, it appears there is a need to
develop, implement and evaluate interventions that use
a “patient-centered approach” whereby patients become
engaged and involved based on their interests and what
is available to them within their community. Given the
modifiable nature of these risk factors, it appears a study
that considers patient preferences would have strong
potential to impact health through lifestyle modifications
geared toward reducing the risk of MetS, prediabetes
and cardiovascular disease. Relatedly, our findings have
implications for reducing the risk factors associated
with MetS, which could decrease the high rates of
cardiovascular mortality experienced by women. The
public health and clinical significance of this study is
in the identification of strategies for early detection and

www.aurora.org/jpcrr

61

treatment of MetS and prevention of prediabetes and
cardiovascular disease.
The novel intervention of the Heart WATCH program
is its patient-centered multidisciplinary approach to
improving women’s health. Participants entered into a
14-week program to mitigate the risk factors associated
with MetS, prediabetes and cardiovascular disease. This
program takes into account patient preferences and
makes an impact on women’s health through lifestyle
modification and risk reduction. This multidisciplinary
program proved to improve self-reported measures of
diet/nutrition, exercise, general health and quality of
life. Biometric measures of weight, waist circumference,
cholesterol and triglycerides also improved. Improvements
in BMI and LDL cholesterol were found but were not
significant statistically. Individual patient change from
before to after program intervention revealed that even
though many women were still obese or morbidly
obese, their clinical outcome status improved over the
course of treatment. Finally, three participants who
initially met the diagnostic definition of MetS no longer
did after completion of the Heart WATCH intervention.
Understanding how individual improvements on
biometric measures can lead to an overall lowering of
diabetes and cardiovascular risk, not only in the short
term but over a more extended follow-up period, is an
important focus for program design and evaluation.
Patients who meet criteria for MetS constitute a group
experiencing an “elevated risk” for chronic health
conditions. These patients have an opportunity for
secondary prevention of additional severe morbidities
such as type 2 diabetes mellitus and coronary vascular
disease. Interventions similar to Heart WATCH have
previously demonstrated the ability to reduce the risk
factors that diagnose a patient with MetS.26 The economic
benefit of preventing these conditions from developing
has been shown to decrease long-term health costs.27 The
U.S. Preventive Services Task Force’s Guide to Clinical
Preventive Services defines “secondary prevention
measures” as those provided to individuals to prevent the
onset of a targeted condition.28 Though diagnostic billing
codes exist for MetS, it is important to recognize that
none of the individual component risk factors that make
up MetS, when taken separately, meet the criteria for a
disease diagnosis. Through the Heart WATCH program,
we attempted to identify women with elevated risk profiles
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but who were as-yet preclinical for diagnosable diabetes
and cardiovascular problems, and provide an intervention
to help prevent these diseases from manifesting.
Given the retrospective nature of our study, we are
limited in making causal inferences. Another limitation
is that some data were self-reported, which could suffer
from participant reporting bias; however, laboratory
biometrics also were reported as a more objective
assessment of patient health status. Participants were a
self-selected group of patients seeking help for weight
management. Because patients entered into Heart
WATCH over several years, factors such as time of year,
economy, employment and other possible unrecognized
factors were not controlled. In addition, we did not
incorporate a comparison group to demonstrate that
Heart WATCH participants changed differentially than
a comparably matched group of nonparticipants. Still,
present evaluation of the Heart WATCH program does
provide guidance for the design of future interventions,
including a systematic assessment that might resolve
some of this study’s limitations.

CONCLUSIONS

This study assessed the impact of a lifestyle modification
program geared toward reducing the risk of chronic
health conditions for women with components of
metabolic syndrome. Preliminary results of this program
are encouraging and warrant further study. There
remains a need to better understand metabolic syndrome
and its impact on women’s health. Patient-centered and
culturally appropriate approaches to weight loss hold
tremendous promise and merit further investigation.
Patient-Friendly Recap
• Certain health conditions — including high blood
pressure, insulin resistance, high blood sugar,
abnormal cholesterol levels and excess body fat
at the waist — are known to increase risk of heart
disease, stroke and diabetes.
• Metabolic syndrome is a term used to describe
the presence of several of these risk factors.
• The authors found that patients at risk for
metabolic syndrome can improve their
conditional status by participating in a 14-week
clinically managed lifestyle program.
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